Upregulation of serum miR 155 and miR 30c as a Potential Biomarker for Alzheimer’s Disease

Abstract Alzheimer's disease (AD), the most common type of dementia, is a serious neurodegenerative disorder for which there is currently no cure. However, available medications can help alleviate the symptoms of the disease. Therefore, it is essential to promptly and accurately diagnose the condition and understand the molecular mechanisms involved in its progression. Disruption of microRNAs (miRNAs) is implicated in the development of neurodegenerative conditions, such as Alzheimer's disease (AD). The research was carried out in order to determine the significance of Mir 30c, and Mir 155 in serving as a diagnostic biomarker The microarray data set GSE138260 was obtained from the Gene Expression Omnibus (GEO) database hosted by the National Center for Biotechnology Information (NCBI) In order to determine gene ontologies, pathways, and networks, one must conduct a comprehensive analysis Blood samples were collected from 30 individuals with AD and 30 individuals without the condition. RNA was extracted from the serum samples, converted to cDNA, and then the real-time PCR method was used to measure the expression level of Mir 30c and Mir 155 . The study's findings indicated that the copy number levels of copy number levels of Mir 30c and Mir 155 were increased. Bioinformatics analysis revealed that these microRNA target pathways are associated with Alzheimer's disease. The cut-off value for this Mir´s demonstrates the trade-off between sensitivity and specificity in diagnostic testing.